Unicycive Therapeutics, Inc.
UNCY
$5.86
-$0.14-2.33%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -16.02% | -10.40% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.44% | -12.84% | |||
| Operating Income | -5.44% | 12.84% | |||
| Income Before Tax | 6.76% | -1,231.05% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 6.76% | -1,231.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.76% | -1,231.05% | |||
| EBIT | -5.44% | 12.84% | |||
| EBITDA | -5.39% | 12.83% | |||
| EPS Basic | 36.52% | -1,299.31% | |||
| Normalized Basic EPS | 36.49% | -1,173.77% | |||
| EPS Diluted | 36.52% | -4.44% | |||
| Normalized Diluted EPS | 36.49% | -1,237.15% | |||
| Average Basic Shares Outstanding | 46.85% | 5.31% | |||
| Average Diluted Shares Outstanding | 46.85% | -0.66% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||